Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Study Purpose
This partially randomized phase I/II trial studies the side effects and the best dose of anti-endoglin monoclonal antibody TRC105 when given together with bevacizumab and to see how well they work in treating patients with glioblastoma multiforme that has come back. Monoclonal antibodies, such as anti-endoglin monoclonal antibody TRC105 and bevacizumab, may find tumor cells and help kill them. Giving anti-endoglin monoclonal antibody TRC105 together with bevacizumab may be an effective treatment for glioblastoma multiforme.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 18 Years and Over |
| Gender | All |
Inclusion Criteria:
- - Histological confirmation of grade 3 or 4 glioma, including astrocytoma, oligodendroglioma, and mixed gliomas, as determined by pre-registration central pathology review (Phase I) - Histological confirmation of glioblastoma multiforme (grade 4 astrocytoma) as determined by pre-registration central pathology review; note: gliosarcomas and other grade 4 astrocytoma variants (e.g., giant cell) are eligible; glioblastoma (GBM) with oligodendroglial features are NOT PERMITTED in this study if they are 1p19q co-deleted; sites submitting GBM with oligodendroglial features will be asked to provide results of 1p/19q co-deletion status (Phase II) - Evidence of tumor progression by MRI or computed tomography (CT) scan following radiation therapy or following the most recent anti-tumor therapy; note: patients who have had surgical treatment at recurrence are eligible if they had a resection with measurable or non-measurable residual disease on postoperative imaging or if there is imaging evidence of disease progression as compared to the first postoperative scan.
- - Measurable or evaluable disease by gadolinium MRI or contrast CT scan; note: patients who have had a gross total resection (GTR) are eligible on the basis of evaluable disease.
- - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2.
- - Absolute neutrophil count (ANC) >= 1,500/mm^3.
- - Platelet count >= 100,000/mm^3.
- - White blood cells (WBC) >= 3,000/mL.
- - Hemoglobin >= 10.0 g/dL; note: this level may be reached by transfusion.
- - Total bilirubin =< institutional upper limit of normal (ULN) - Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2 x ULN.
- - Creatinine =< ULN.
- - Life expectancy >= 12 weeks.
- - Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only.
- - Urine protein creatinine (UPC) ratio < 1; note: urine protein must be screened by urine analysis for UPC ratio; for UPC ratio >= 1.0, 24-hour urine protein must be obtained and the level should be < 1,000 mg for registration.
- - Fixed or decreasing dose of corticosteroids (or no corticosteroids) >= 7 days prior to registration.
- - Calculated glomerular filtration rate (GFR) must be >= 60 ml/min; GFR will be calculated as needed per institutional guidelines.
- - Any number of prior chemotherapy regimens for recurrent disease (Phase I); =< 1 chemotherapy or other non-antiangiogenic regimen for recurrent disease (Phase II) - Last dose of bevacizumab >= 2 weeks prior to registration (Phase I); note: for the phase II study only, prior exposure to bevacizumab is not allowed.
- - Surgery >= 4 weeks prior to registration.
- - Completion of radiation therapy >= 12 weeks prior to registration and prior chemotherapy >= 4 weeks prior to registration (>= 6 weeks from nitrosourea-containing regimens) - Small molecular cell cycle inhibitors >= 2 weeks from registration.
- - Ability to provide informed written consent.
- - Ability to complete questionnaire(s) by themselves or with assistance.
- - Willing to return to enrolling institution for follow-up.
- - Willing to discontinue use of medications that inhibit platelet function >= 10 days prior to registration; aspirin at doses greater than 325 mg/day must be discontinued >= 10 days prior to registration and avoided through the study; note: nonsteroidal anti-inflammatory drug (NSAID) medications are recommended in place of aspirin; if NSAIDs or aspirin are used, histamine (H)-2 blockers and proton pump inhibitor (PPI) medications are recommended.
- - Willing to provide mandatory blood and tissue samples for correlative research
purposes (Phase I and II)
Exclusion Criteria:
- Any of the following: - Pregnant women.
- - Nursing women.
- - Men or women of childbearing potential who are unwilling to employ adequate contraception throughout the duration of the study and for at least 6 months after treatment has ended.
- - Prior hypersensitivity to bevacizumab or toxicity requiring discontinuation of bevacizumab (Phase I) - Any prior exposure to any VEGF or VEGF inhibitor including, but not limited to, bevacizumab, cediranib, vandetanib, sunitinib, pazopanib, aflibercept, or sorafenib (Phase II) - Prior hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies (Phase I and II) - Prior hypersensitivity to triptan derivatives (Phase I and II) - Other active malignancy =< 3 years prior to registration; exceptions: non-melanotic skin cancer or carcinoma-in-situ of the cervix; note: if there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer.
- - Uncontrolled infection.
- - Immunocompromised patients or patients known to be human immunodeficiency virus (HIV) positive and currently receiving combination antiretroviral therapy; patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial.
- - Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the prescribed regimens.
- - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
- - History of hypertensive crisis or hypertensive encephalopathy.
- - Clinically significant cardiovascular disease defined as follows: - Inadequately controlled hypertension (i.e., systolic blood pressure [SBP] > 160 mm Hg and/or diastolic blood pressure [DBP] > 90 mm Hg despite antihypertensive therapy) - History of cerebrovascular accident (CVA) within 6 months.
- - Myocardial infarction or unstable angina within 6 months.
- - New York Heart Association classification II, III, or IV cardiovascular disease.
- - Serious and inadequately controlled cardiac arrhythmia.
- - Significant vascular disease (i.e., aortic aneurysm, history of aortic dissection) - Clinically significant peripheral vascular disease.
- - Evidence or history of bleeding diathesis (greater than normal risk of bleeding, i.e., hereditary hemorrhagic telangiectasia type I or HHT-1) or coagulopathy in the absence of therapeutic anti-coagulation or any hemorrhage/bleeding event > grade 3 within 4 weeks prior to registration; note: patients with full-dose anticoagulants are eligible provided the patient has been on a stable dose for at least 2 weeks of low molecular weight heparin; therapeutic Coumadin and aspirin doses > 325 mg daily are not allowed.
- - Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm.
- - Prior treatment with TRC105.
- - Serious or non-healing wound, active ulcer, or untreated bone fracture.
- - History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess =< 6 months prior to registration.
- - History of invasive procedures defined as follows: - Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to registration.
- - Anticipation of need for major surgical procedures during the study.
- - Core biopsy =< 7 days prior to registration.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT01648348 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 1/Phase 2 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
National Cancer Institute (NCI) |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Evanthia Galanis |
| Principal Investigator Affiliation | Alliance for Clinical Trials in Oncology |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
NIH |
| Overall Status | Completed |
| Countries | United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm |
PRIMARY OBJECTIVES:
- I. To establish a maximum tolerated dose (MTD) of TRC105 (anti-endoglin monoclonal antibody TRC105) combined with bevacizumab in this patient population.
- II. To assess the safety and adverse events of TRC105 in combination with bevacizumab in this patient population.
- III. To determine the efficacy of TRC105 in combination with bevacizumab in recurrent glioblastoma as measured by progression-free survival and compare it with the efficacy of bevacizumab alone in this patient population.
- I. To assess the proportion of patients, who are progression free at 6 months, treated with TRC105 in combination with bevacizumab as compared to bevacizumab alone.
- II. To assess the overall survival of patients treated with TRC105 in combination with bevacizumab compared to bevacizumab alone.
- III. To compare the impact of the treatment on the patients quality of life (QOL) using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QLQ)-C15-Palliative Care (PAL) and QLQ-brain neoplasm (BN)20 Patient Questionnaires.
- IV. To estimate patient recommendations for study participation to others using the Was It Worth It (WIWI) Questionnaire.
- I. To evaluate the pharmacokinetics of TRC105.
- II. To evaluate the immunogenicity of TRC105.
- III. To determine the relationship between tumor biomarkers, circulating biomarkers of vascular response and vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) single-nucleotide polymorphisms (SNPs) in predicting efficacy and/or toxicity of treatment.
- IV. To assess the utility of magnetic resonance imaging (MRI) imaging including apparent diffusion coefficient (ADC) as a predictor of response and survival.
- V. To assess the utility of dynamic contrast enhanced (DCE) MRI as a predictor of response to bevacizumab with or without TRC105.
- I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Arms
Experimental: Arm I (bevacizumab and TRC105)
Patients receive bevacizumab IV over 30-90 minutes on day 1 and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 8 and 11 of course 1 and days 1 and 8 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Active Comparator: Arm II (bevacizumab)
Patients receive bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Interventions
Biological: - Anti-Endoglin Chimeric Monoclonal Antibody TRC105
Given IV
Biological: - Bevacizumab
Given IV
Other: - Laboratory Biomarker Analysis
Correlative studies
Other: - Pharmacological Study
Correlative studies
Other: - Quality-of-Life Assessment
Ancillary studies
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Status
Address
Saint Jude Medical Center
Fullerton, California, 92835
Status
Address
Saint Joseph Hospital - Orange
Orange, California, 92868
Status
Address
Sharp Memorial Hospital
San Diego, California, 92123
Status
Address
UCSF Medical Center-Mount Zion
San Francisco, California, 94115
Status
Address
UCSF Medical Center-Parnassus
San Francisco, California, 94143
Status
Address
Greenwich Hospital
Greenwich, Connecticut, 06830
Status
Address
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, 06105
Status
Address
Stamford Hospital/Bennett Cancer Center
Stamford, Connecticut, 06904
Status
Address
Beebe Medical Center
Lewes, Delaware, 19958
Status
Address
Christiana Gynecologic Oncology LLC
Newark, Delaware, 19713
Status
Address
Delaware Clinical and Laboratory Physicians PA
Newark, Delaware, 19713
Status
Address
Helen F Graham Cancer Center
Newark, Delaware, 19713
Status
Address
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Status
Address
Regional Hematology and Oncology PA
Newark, Delaware, 19713
Status
Address
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Status
Address
Beebe Health Campus
Rehoboth Beach, Delaware, 19971
Status
Address
Nanticoke Memorial Hospital
Seaford, Delaware, 19973
Status
Address
Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware, 19801
Status
Address
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980
Status
Address
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Status
Address
Florida Hospital Orlando
Orlando, Florida, 32803
Status
Address
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Status
Address
Kootenai Medical Center
Coeur d'Alene, Idaho, 83814
Status
Address
Kootenai Cancer Center
Post Falls, Idaho, 83854
Status
Address
Kootenai Cancer Clinic
Sandpoint, Idaho, 83864
Status
Address
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Status
Address
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Status
Address
Illinois CancerCare-Canton
Canton, Illinois, 61520
Status
Address
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Status
Address
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Status
Address
Centralia Oncology Clinic
Centralia, Illinois, 62801
Status
Address
Northwestern University
Chicago, Illinois, 60611
Status
Address
Cancer Care Center of Decatur
Decatur, Illinois, 62526
Status
Address
Decatur Memorial Hospital
Decatur, Illinois, 62526
Status
Address
Crossroads Cancer Center
Effingham, Illinois, 62401
Status
Address
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Status
Address
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201
Status
Address
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Status
Address
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
Status
Address
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois, 60026
Status
Address
Hematology Oncology Associates of Illinois-Highland Park
Highland Park, Illinois, 60035
Status
Address
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois, 60035
Status
Address
Presence Saint Mary's Hospital
Kankakee, Illinois, 60901
Status
Address
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Status
Address
NorthShore Hematology Oncology-Libertyville
Libertyville, Illinois, 60048
Status
Address
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Status
Address
Garneau, Stewart C MD (UIA Investigator)
Moline, Illinois, 61265
Status
Address
Spector, David MD (UIA Investigator)
Moline, Illinois, 61265
Status
Address
Trinity Medical Center
Moline, Illinois, 61265
Status
Address
Illinois Cancer Specialists-Niles
Niles, Illinois, 60714
Status
Address
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Status
Address
Radiation Oncology of Northern Illinois
Ottawa, Illinois, 61350
Status
Address
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
Status
Address
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Status
Address
Methodist Medical Center of Illinois
Peoria, Illinois, 61603
Status
Address
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Status
Address
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois, 61615
Status
Address
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Status
Address
Illinois CancerCare-Peru
Peru, Illinois, 61354
Status
Address
Valley Radiation Oncology
Peru, Illinois, 61354
Status
Address
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Status
Address
Hematology Oncology Associates of Illinois - Skokie
Skokie, Illinois, 60076
Status
Address
Central Illinois Hematology Oncology Center
Springfield, Illinois, 62702
Status
Address
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Status
Address
Springfield Clinic
Springfield, Illinois, 62702
Status
Address
Memorial Medical Center
Springfield, Illinois, 62781
Status
Address
Cancer Care Specialists of Illinois-Swansea
Swansea, Illinois, 62226
Status
Address
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois, 60555
Status
Address
Michiana Hematology Oncology PC-Crown Point
Crown Point, Indiana, 46307
Status
Address
Elkhart Clinic
Elkhart, Indiana, 46514-2098
Status
Address
Michiana Hematology Oncology PC-Elkhart
Elkhart, Indiana, 46514
Status
Address
Elkhart General Hospital
Elkhart, Indiana, 46515
Status
Address
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
Status
Address
Community Howard Regional Health
Kokomo, Indiana, 46904
Status
Address
IU Health La Porte Hospital
La Porte, Indiana, 46350
Status
Address
Memorial Regional Cancer Center Day Road
Mishawaka, Indiana, 46544
Status
Address
Michiana Hematology Oncology PC-Mishawaka
Mishawaka, Indiana, 46545
Status
Address
Saint Joseph Regional Medical Center-Mishawaka
Mishawaka, Indiana, 46545
Status
Address
Michiana Hematology Oncology PC-Plymouth
Plymouth, Indiana, 46563
Status
Address
Reid Health
Richmond, Indiana, 47374
Status
Address
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Status
Address
Michiana Hematology Oncology PC-South Bend
South Bend, Indiana, 46601
Status
Address
South Bend Clinic
South Bend, Indiana, 46617
Status
Address
Northern Indiana Cancer Research Consortium
South Bend, Indiana, 46628
Status
Address
Michiana Hematology Oncology PC-Westville
Westville, Indiana, 46391
Status
Address
Mary Greeley Medical Center
Ames, Iowa, 50010
Status
Address
McFarland Clinic PC-William R Bliss Cancer Center
Ames, Iowa, 50010
Status
Address
Constantinou, Costas L MD (UIA Investigator)
Bettendorf, Iowa, 52722
Status
Address
McFarland Clinic PC-Boone
Boone, Iowa, 50036
Status
Address
Mercy Hospital
Cedar Rapids, Iowa, 52403
Status
Address
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Status
Address
McFarland Clinic PC-Trinity Cancer Center
Fort Dodge, Iowa, 50501
Status
Address
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242
Status
Address
McFarland Clinic PC-Jefferson
Jefferson, Iowa, 50129
Status
Address
McFarland Clinic PC-Marshalltown
Marshalltown, Iowa, 50158
Status
Address
Siouxland Regional Cancer Center
Sioux City, Iowa, 51101
Status
Address
Mercy Medical Center-Sioux City
Sioux City, Iowa, 51104
Status
Address
Saint Luke's Regional Medical Center
Sioux City, Iowa, 51104
Status
Address
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Status
Address
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Status
Address
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Status
Address
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Status
Address
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Status
Address
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Status
Address
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Status
Address
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
Status
Address
Cancer Center of Kansas-Manhattan
Manhattan, Kansas, 66502
Status
Address
Cancer Center of Kansas - McPherson
McPherson, Kansas, 67460
Status
Address
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Status
Address
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
Status
Address
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
Status
Address
Cancer Center of Kansas - Salina
Salina, Kansas, 67401
Status
Address
Cancer Center of Kansas - Wellington
Wellington, Kansas, 67152
Status
Address
Associates In Womens Health
Wichita, Kansas, 67208
Status
Address
Cancer Center of Kansas-Wichita Medical Arts Tower
Wichita, Kansas, 67208
Status
Address
Cancer Center of Kansas - Wichita
Wichita, Kansas, 67214
Status
Address
Via Christi Regional Medical Center
Wichita, Kansas, 67214
Status
Address
Wichita NCI Community Oncology Research Program
Wichita, Kansas, 67214
Status
Address
Cancer Center of Kansas - Winfield
Winfield, Kansas, 67156
Status
Address
Baptist Health Corbin
Corbin, Kentucky, 40701
Status
Address
Oncology Hematology Care Inc-Crestview
Crestview Hills, Kentucky, 41017
Status
Address
Hardin Memorial Hospital
Elizabethtown, Kentucky, 42701
Status
Address
Baptist Health Lexington
Lexington, Kentucky, 40503
Status
Address
Baptist Health Madisonville/Merle Mahr Cancer Center
Madisonville, Kentucky, 42431
Status
Address
Baptist Health Paducah
Paducah, Kentucky, 42003
Status
Address
Eastern Maine Medical Center
Bangor, Maine, 04401
Status
Address
Lafayette Family Cancer Center-EMMC
Brewer, Maine, 04412
Status
Address
Maine Center for Cancer Medicine-Scarborough
Scarborough, Maine, 04074
Status
Address
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Status
Address
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
Status
Address
Massachusetts General Hospital
Charlestown, Massachusetts, 02129
Status
Address
Bixby Medical Center
Adrian, Michigan, 49221
Status
Address
Hickman Cancer Center
Adrian, Michigan, 49221
Status
Address
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106-0995
Status
Address
Bronson Battle Creek
Battle Creek, Michigan, 49017
Status
Address
Beaumont Hospital-Dearborn
Dearborn, Michigan, 48124
Status
Address
Saint John Hospital and Medical Center
Detroit, Michigan, 48236
Status
Address
Hurley Medical Center
Flint, Michigan, 48502
Status
Address
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Status
Address
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Status
Address
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Status
Address
Allegiance Health
Jackson, Michigan, 49201
Status
Address
Borgess Medical Center
Kalamazoo, Michigan, 49001
Status
Address
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Status
Address
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Status
Address
Sparrow Hospital
Lansing, Michigan, 48912
Status
Address
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Status
Address
Mercy Memorial Hospital
Monroe, Michigan, 48162
Status
Address
Toledo Clinic Cancer Centers-Monroe
Monroe, Michigan, 48162
Status
Address
Mercy Health Mercy Campus
Muskegon, Michigan, 49444
Status
Address
Lakeland Community Hospital
Niles, Michigan, 49120
Status
Address
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Status
Address
Lake Huron Medical Center
Port Huron, Michigan, 48060
Status
Address
Spectrum Health Reed City Hospital
Reed City, Michigan, 49677
Status
Address
Saint Mary's of Michigan
Saginaw, Michigan, 48601
Status
Address
Lakeland Hospital
Saint Joseph, Michigan, 49085
Status
Address
Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085
Status
Address
Munson Medical Center
Traverse City, Michigan, 49684
Status
Address
Saint John Macomb-Oakland Hospital
Warren, Michigan, 48093
Status
Address
Ann Arbor Hematology -Oncology Associates
Ypsilanti, Michigan, 48197
Status
Address
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Status
Address
Mercy Hospital
Coon Rapids, Minnesota, 55433
Status
Address
Essentia Health Cancer Center
Duluth, Minnesota, 55805
Status
Address
Essentia Health Saint Mary's Medical Center
Duluth, Minnesota, 55805
Status
Address
Miller-Dwan Hospital
Duluth, Minnesota, 55805
Status
Address
Saint Luke's Hospital of Duluth
Duluth, Minnesota, 55805
Status
Address
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Status
Address
Unity Hospital
Fridley, Minnesota, 55432
Status
Address
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Status
Address
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Status
Address
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Status
Address
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Status
Address
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Status
Address
Health Partners Inc
Minneapolis, Minnesota, 55454
Status
Address
New Ulm Medical Center
New Ulm, Minnesota, 56073
Status
Address
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Status
Address
Mayo Clinic
Rochester, Minnesota, 55905
Status
Address
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota, 56303
Status
Address
Saint Cloud Hospital
Saint Cloud, Minnesota, 56303
Status
Address
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, 55416
Status
Address
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Status
Address
Regions Hospital
Saint Paul, Minnesota, 55101
Status
Address
United Hospital
Saint Paul, Minnesota, 55102
Status
Address
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
Status
Address
Lakeview Hospital
Stillwater, Minnesota, 55082
Status
Address
Ridgeview Medical Center
Waconia, Minnesota, 55387
Status
Address
Rice Memorial Hospital
Willmar, Minnesota, 56201
Status
Address
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
Status
Address
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
Status
Address
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Status
Address
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Status
Address
Capital Region Medical Center-Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
Status
Address
Washington University School of Medicine
Saint Louis, Missouri, 63110
Status
Address
Missouri Baptist Medical Center
Saint Louis, Missouri, 63131
Status
Address
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri, 63670
Status
Address
Missouri Baptist Sullivan Hospital
Sullivan, Missouri, 63080
Status
Address
Missouri Baptist Outpatient Center-Sunset Hills
Sunset Hills, Missouri, 63127
Status
Address
Billings Clinic Cancer Center
Billings, Montana, 59101
Status
Address
Montana Cancer Consortium NCORP
Billings, Montana, 59101
Status
Address
Saint Vincent Healthcare
Billings, Montana, 59101
Status
Address
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Status
Address
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Status
Address
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Status
Address
Saint Peter's Community Hospital
Helena, Montana, 59601
Status
Address
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Status
Address
Saint Patrick Hospital - Community Hospital
Missoula, Montana, 59802
Status
Address
Community Medical Hospital
Missoula, Montana, 59804
Status
Address
University of Nebraska Medical Center
Omaha, Nebraska, 68198
Status
Address
New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire, 03301
Status
Address
New Hampshire Oncology Hematology PA-Hooksett
Hooksett, New Hampshire, 03106
Status
Address
LRGHealthcare-Lakes Region General Hospital
Laconia, New Hampshire, 03246
Status
Address
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Status
Address
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
Status
Address
MD Anderson Cancer Center at Cooper-Voorhees
Voorhees, New Jersey, 08043
Status
Address
Hematology Oncology Associates of Central New York-Auburn
Auburn, New York, 13021
Status
Address
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, 13057
Status
Address
Mount Sinai Hospital
New York, New York, 10029
Status
Address
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065
Status
Address
State University of New York Upstate Medical University
Syracuse, New York, 13210
Status
Address
Hematology Oncology Associates of Central New York-Onondaga Hill
Syracuse, New York, 13215
Status
Address
Wayne Memorial Hospital
Goldsboro, North Carolina, 27534
Status
Address
Kinston Medical Specialists PA
Kinston, North Carolina, 28501
Status
Address
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157
Status
Address
Altru Cancer Center
Grand Forks, North Dakota, 58201
Status
Address
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Status
Address
Toledo Clinic Cancer Centers-Bowling Green
Bowling Green, Ohio, 43402
Status
Address
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Status
Address
Oncology Hematology Care Inc-Eden Park
Cincinnati, Ohio, 45202
Status
Address
Oncology Hematology Care Inc-Mercy West
Cincinnati, Ohio, 45211
Status
Address
Oncology Hematology Care Inc - Anderson
Cincinnati, Ohio, 45230
Status
Address
Oncology Hematology Care Inc-Kenwood
Cincinnati, Ohio, 45236
Status
Address
Oncology Hematology Care Inc-Blue Ash
Cincinnati, Ohio, 45242
Status
Address
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, 43214
Status
Address
Riverside Methodist Hospital
Columbus, Ohio, 43214
Status
Address
Columbus NCI Community Oncology Research Program
Columbus, Ohio, 43215
Status
Address
Grant Medical Center
Columbus, Ohio, 43215
Status
Address
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Status
Address
Mount Carmel Health Center West
Columbus, Ohio, 43222
Status
Address
Doctors Hospital
Columbus, Ohio, 43228
Status
Address
Good Samaritan Hospital - Dayton
Dayton, Ohio, 45406
Status
Address
Miami Valley Hospital
Dayton, Ohio, 45409
Status
Address
Samaritan North Health Center
Dayton, Ohio, 45415
Status
Address
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, 43015
Status
Address
Delaware Radiation Oncology
Delaware, Ohio, 43015
Status
Address
Grady Memorial Hospital
Delaware, Ohio, 43015
Status
Address
Oncology Hematology Care Inc-Healthplex
Fairfield, Ohio, 45014
Status
Address
Blanchard Valley Hospital
Findlay, Ohio, 45840
Status
Address
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Status
Address
Wayne Hospital
Greenville, Ohio, 45331
Status
Address
Kettering Medical Center
Kettering, Ohio, 45429
Status
Address
Fairfield Medical Center
Lancaster, Ohio, 43130
Status
Address
Lima Memorial Hospital
Lima, Ohio, 45804
Status
Address
Marietta Memorial Hospital
Marietta, Ohio, 45750
Status
Address
OneHealth Marion General Hospital
Marion, Ohio, 43302
Status
Address
Toledo Clinic Cancer Centers-Maumee
Maumee, Ohio, 43537
Status
Address
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
Maumee, Ohio, 43537
Status
Address
Knox Community Hospital
Mount Vernon, Ohio, 43050
Status
Address
Licking Memorial Hospital
Newark, Ohio, 43055
Status
Address
Newark Radiation Oncology
Newark, Ohio, 43055
Status
Address
Saint Charles Hospital
Oregon, Ohio, 43616
Status
Address
Toledo Clinic Cancer Centers-Oregon
Oregon, Ohio, 43616
Status
Address
Southern Ohio Medical Center
Portsmouth, Ohio, 45662
Status
Address
Springfield Regional Medical Center
Springfield, Ohio, 45505
Status
Address
Flower Hospital
Sylvania, Ohio, 43560
Status
Address
Mercy Hospital of Tiffin
Tiffin, Ohio, 44883
Status
Address
Saint Vincent Mercy Medical Center
Toledo, Ohio, 43608
Status
Address
University of Toledo
Toledo, Ohio, 43614
Status
Address
Toledo Community Hospital Oncology Program CCOP
Toledo, Ohio, 43617
Status
Address
Mercy Saint Anne Hospital
Toledo, Ohio, 43623
Status
Address
Toledo Clinic Cancer Centers-Toledo
Toledo, Ohio, 43623
Status
Address
Upper Valley Medical Center
Troy, Ohio, 45373
Status
Address
Fulton County Health Center
Wauseon, Ohio, 43567
Status
Address
Saint Ann's Hospital
Westerville, Ohio, 43081
Status
Address
Genesis Healthcare System Cancer Care Center
Zanesville, Ohio, 43701
Status
Address
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Status
Address
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma, 74146
Status
Address
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Status
Address
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Status
Address
PinnacleHealth Cancer Center-Community Campus
Harrisburg, Pennsylvania, 17109
Status
Address
Reading Hospital
West Reading, Pennsylvania, 19611
Status
Address
Greenville Health System Cancer Institute-Easley
Easley, South Carolina, 29640
Status
Address
Greenville Health System Cancer Institute-Andrews
Greenville, South Carolina, 29605
Status
Address
Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina, 29605
Status
Address
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, 29605
Status
Address
Greenville Memorial Hospital
Greenville, South Carolina, 29605
Status
Address
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, 29615
Status
Address
Greenville Health System Cancer Institute-Greer
Greer, South Carolina, 29650
Status
Address
Greenville Health System Cancer Institute-Seneca
Seneca, South Carolina, 29672
Status
Address
Greenville Health System Cancer Institute-Spartanburg
Spartanburg, South Carolina, 29307
Status
Address
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Status
Address
University Medical Center Brackenridge
Austin, Texas, 78701
Status
Address
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Status
Address
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
Status
Address
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Status
Address
Fredericksburg Oncology Inc
Fredericksburg, Virginia, 22401
Status
Address
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Status
Address
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
Status
Address
Community Memorial Hospital
Menomonee Falls, Wisconsin, 53051
Status
Address
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Status
Address
ProHealth D N Greenwald Center
Mukwonago, Wisconsin, 53149
Status
Address
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
Status
Address
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin, 53066
Status
Address
ProHealth Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188
Status
Address
Rocky Mountain Oncology
Casper, Wyoming, 82609
Status
Address
Big Horn Basin Cancer Center
Cody, Wyoming, 82414
Status
Address
Billings Clinic-Cody
Cody, Wyoming, 82414
Status
Address
Welch Cancer Center
Sheridan, Wyoming, 82801
